503B FDA-Registered Facility Manufacturing Veterinary Medications

Available in the U.S. & Ready to Ship!

Injectable Omeprazole for Horses

Over 200,000 doses sold globally!

We have partnered with the Bova group to bring a unique formulation of omeprazole injection for horses to the US. This is the same omeprazole injection that Bova has used in Australia and the UK since 2017.

Benefits of Omeprazole Injection Suspension

Epicur Bova Omeprazole

Order today!

We offer two simple, streamlined ways to order our Omeprazole Injection Suspension for your patients and practice. 

  • Online via iFill

    Current iFill users can place an order online. This is our most recommended way of ordering. View pricing, expiration dates, and order seamlessly!

    If you're a new user, register for an account.*
    *registration for iFill takes up to 48 hours

  • Call Your Order In

    Veterinarians can also call Epicur at
    888.508.5032

Additional Equine Medications from Stokes Pharmacy

Our sister division, Stokes Pharmacy also has select medications available for horse health, including Ertugliflozin, Esomeprazole, and Doxycycline Monohydrate. Learn more about available medications. 

Download our most up-to-date equine medication list

Important Safety Information: This is an oil-based intramuscular injection that can cause transient non-painful swelling after administration. It is not to be administered IM into the pectoral muscle. Omeprazole may increase the rate of intestinal complications when administered concurrently with phenylbutazone to horses with EGGD or equine gastric ulcer syndrome. This product has not been studied on pregnant or nursing mares.  

Downloads and Resources

Omeprazole Injection Drug Information Sheet
About the Bova formulation of injectable omeprazole manufactured at Epicur Pharma
Omeprazole Injection Brochure
Learn more, including the differences between this formulation as well as other formulations available on the market



Injectable Omeprazole Interview
with Dr. Camilla Jamieson

Watch this session with Dr. Camilla Jamieson as she addresses frequently asked questions about Injectable Omeprazole and provides guidance for veterinarians.

Omeprazole Injection Optimal Administration Sites
A clear, easy-to-follow visual guide designed to support safe and accurate administration.
Omeprazole Injection 5V7 Day Study Chart
This streamlined reference was designed to help veterinarians compare treatment timelines at a glance.

Frequently Asked Questions

Injectable omeprazole is now used widely for glandular gastric disease. It is also used in severe or refractory squamous disease. Many owners prefer a weekly injection to having to administer daily oral medication and the injection is useful in situations where compliance with oral treatment is expected to be poor.

Injectable omeprazole is not intended for preventing gastric ulcers in horses.

Injectable omeprazole is intended for short-term use and is not recommended for extended or indefinite therapy as the risk of reactions is likely to increase with repeated injection of the same sites. Although they are not as potent, it should be possible to prevent gastric disease with oral proton pump inhibitors.

Epicur’s omeprazole injection begins working almost immediately.

Injectable omeprazole differs from oral formulations in both how it’s administered and how it works. Because it is given as an injectable, it bypasses the gastrointestinal tract so the whole dose reaches the systemic circulation rather than around 10% of the dose with oral preparations. This results in more consistent and more profound gastric acid suppression. It also eliminates challenges with palatability and handling, offering veterinarians and owners a practical alternative when compliance is an issue.

The dose of injectable omeprazole is 4 mg/kg intramuscular (gluteal or neck preferred, avoid pectorals) once every 5–7 days

The pectoral muscles are too small to comfortably accommodate a 20 mL injection. The pecs will consistently swell with that amount of volume. According to reviewed and published data, it is recommended to give the injection intramuscularly in the upper middle gluteal muscles or the neck, where there is sufficient muscle mass to tolerate the volume.

The hamstring area is also a smaller muscle mass and the risk of pain or swelling is higher. Soreness in this area will have a greater effect on soundness and performance than the recommended sites.

Based on published studies, it is recommended to use an 18-gauge needle.

While the risk with other injectable omeprazole products has been reported to be high, with the Bova formulation only 1-6% of injections were associated with localized swelling in published studies.

There are no long-term reactions based on published studies. Injection site reactions typically resolve spontaneously within a few days.

It is important to ensure the suspension is well mixed by shaking it thoroughly. Warming the vial to body temperature before administration will help with reconstitution, will make the formulation easier to inject, and may reduce local irritation. It can also be helpful to warm up the horse’s muscles beforehand—walking or lunging the horse for 10–15 minutes prior to injection may improve muscle circulation and comfort during administration. Ensure the site is aseptically prepared or at least cleaned prior to injection.

The injectable omeprazole available from Epicur Pharma is manufactured under cGMP standards, which allows for longer, validated expiration dates compared with traditional compounding pharmacies that assign shorter, beyond-use dates. Veterinarians can easily view the current expiration dating for each lot, along with real-time pricing, through Epicur’s free online ordering platform, iFill. This system allows clinics to review product details before placing an order, ensuring transparency and helping with inventory planning.

Get ahead of the herd.

Subscribe to Epicur Pharma & Stokes Pharmacy updates!

Become a Stokes Healthcare subscriber to stay up to date on all the latest product announcements, company news, industry updates, and veterinary care best practices.

Disclaimer: By signing up, you are agreeing to receive emails from both Epicur Pharma and Stokes Pharmacy, two divisions of Stokes Healthcare.

Upcoming and On-Demand Equine Webinars

Beyond the Ulcer: Understanding Equine Gastric Disease with Camilla Jamieson

Expert Veterinary Insights on ESGD, EGGD, and Modern Treatment Approaches

Dr. Camilla Jamieson always knew she wanted to be a horse vet. Growing up around horses, she started learning about equine medicine as a kid and her passion for a career in the field was reinforced when a few equine veterinarians took her under their wing. Today, she is an internationally trained equine internal medicine specialist and trusted leader in the field, gaining expertise from her work in demanding equine medical environments all across the globe.

We’ve been lucky enough to partner with her for several educational webinars, and now we’ve sat down with her to talk one-on-one about the intricacies of Equine Gastric Ulcer Syndrome (EGUS) and why effective diagnosis and management require more than a one-size-fits-all approach.

What are some of the biggest misconceptions about Equine Gastric Ulcer Syndrome you see among horse owners and veterinary professionals?

One of the biggest misconceptions is that we can diagnose and treat equine gastric ulcers based on clinical signs alone. Many horses are treated for ulcers because of behavioral changes or performance issues, but those signs can be caused by a wide range of conditions. Without a gastroscopic examination, it can be difficult to determine whether ulcers are truly the underlying problem.

Another challenge is that all gastric ulcers are often treated as though they’re the same disease. They’re not. The stomach has two distinct regions, and ulcers in those areas can behave very differently. The glandular and squamous portions of the stomach often require different treatment protocols, treatment durations, and management strategies. When treatment is selected without identifying the type and location of the ulcer, there’s a risk of using the wrong therapy or not treating long enough to achieve meaningful healing. 

I also encourage veterinarians and owners to think about equine gastric disease as a long-term management condition. In many horses, especially performance horses, it’s not a matter of treating once and never dealing with it again. Managing the underlying risk factors is often just as important as treating the active disease.

How has vets’ understanding of EGUS changed since you started in the field, and how has that impacted diagnosis and treatment?

Fifteen years ago, most discussions around EGUS centered on acid suppression and oral omeprazole therapy. Today, our understanding is much broader. We know much more about how stress affects gastric health, how feeding practices influence acid production, and how horses’ natural grazing behavior impacts the stomach environment. 

That expanded understanding has changed how we approach equine gastric disease management. We now recognize that diet, forage availability, stress reduction, turnout, and overall management are critical components of successful long-term care. At the same time, veterinarians have more therapeutic options available, including different proton pump inhibitors and treatment approaches tailored to individual cases. 

While the fundamentals of diagnosis remain the same, access to gastroscopy has improved significantly. More practitioners have access to endoscopy equipment, making definitive diagnosis of Equine Gastric Ulcer Syndrome more accessible than ever before. 

How do treatment approaches differ between Equine Squamous Gastric Disease (ESGD) and Equine Glandular Gastric Disease (EGGD)?

Understanding the difference between ESGD and EGGD directly impacts treatment selection, expected healing time, client communication, and long-term management. 

For example, many squamous ulcers respond well to omeprazole and may improve within a few weeks. More severe glandular or pyloric lesions often require much longer treatment periods and significantly different expectations. In those cases, I prepare owners for the possibility of months of therapy rather than weeks. 

A definitive diagnosis also helps build client confidence and compliance. When owners can see endoscopic images and understand exactly what is being treated, it becomes much easier to explain why a particular treatment plan is necessary, why healing takes time, and why follow-up evaluations may be required.

You’ve had experience working with extended-release injectable omeprazole before its introduction in the United States. What first drew your attention to this treatment approach?

I went to vet school in England, and the Bova product was already on the market then, so I was aware that it was available. I got hands-on experience with the injectable omeprazole and used it a lot when I worked in the Middle East for four years after my residency. Our medication supply was all Australian products, so we had the Bova products through our Australian supplier. I worked with large stud farms that managed large horse herds, and daily oral medication administration wasn’t always practical. Injectable therapy offered a convenient alternative because multiple horses could be treated on a weekly schedule rather than requiring daily dosing.

That convenience factor stood out immediately. Instead of coordinating daily administration, treatments could often be incorporated into routine veterinary visits. While management practices and owner preferences vary considerably from one region to another, injectable therapy provided a valuable option in situations where consistent oral administration was challenging. 

Based on the research and clinical cases you’ve seen, what types of horses seem to benefit most from injectable omeprazole therapy?

I don’t think benefit is necessarily tied to breed or discipline. Instead, it’s often related to management and practicality. Some horses simply aren’t ideal candidates for daily oral medication because of feeding schedules, travel demands, owner availability, or difficulty maintaining fasting protocols. 

Every case is different. Treatment decisions should be individualized based on the horse, the owner, and the management environment. One of the advantages veterinarians have today is a growing range of therapeutic options that can be matched to the specific needs of each patient.

Injectable Omeprazole for Horses

See all the benefits of our omeprazole and discover why over 200,000 doses have sold globally!

What does current research suggest about the role of injectable omeprazole in managing equine glandular gastric disease?

One area that continues to generate interest is how different formulations can help address some of the challenges associated with oral therapy. For example, one of the limitations of traditional oral omeprazole is that efficacy can be influenced by whether the horse has been fasted. 

Researchers are actively exploring alternative formulations and treatment protocols to improve convenience, consistency, and outcomes. As the evidence base continues to grow, veterinarians are gaining more tools to tailor equine gastric ulcer treatment and prevention strategies to individual horses. 

Once ulcers have healed, what management strategies do you recommend to reduce the risk of recurrence?

My ideal goal is to achieve complete healing through medical therapy and then maintain horses through management changes whenever possible. Some horses will require additional medical support because of their lifestyle or predisposition, but management remains a critical part of long-term success. 

The biggest recurring risk factors I see are stress, illness, diet changes, travel, reduced turnout, and disruptions to a horse’s normal routine. Those factors often occur together, particularly in performance horses. Recognizing periods of increased risk allows veterinarians and owners to proactively adjust management and treatment strategies when appropriate. 

What areas of future equine gastric disease research are you most excited about?

The biggest area of research that I’m really excited about right now is looking at the way esomeprazole paste and the enteric coating is formulated. One of the biggest problems we face with oral omeprazole is that it’s a great drug if it’s fed on an empty stomach, but it’s a really variable and weak drug if the horse’s stomach is full of food. But one of the biggest predictors of creating gastric ulcers is holding horses off feed. It creates a difficult catch-22: you have to fast the horse for the drug to work, but fasting the horse is bad for the disease.

We’re hoping to evaluate how the enteric-coated esomeprazole formulation performs in fasted versus non-fasted horses. Based on early data, it looks like it makes no difference whether it’s fed on an empty stomach or a full stomach. If that holds true, that would be a huge convenience benefit for owners not having to try to add a two-hour fast into their horse’s day, but it would also have major benefits for treating the disease. 

Beyond this research, there are groups that are looking at various treatment protocols, duration of protocols, and use of smaller doses for prevention and management with the injectable omeprazole. Through all of this research and the more we know, the better we are going to be able to tailor individual treatment courses for individual animals.

If you could leave equine veterinarians with one practical takeaway about diagnosing and managing EGUS more effectively, what would it be?

Prepare owners for the long haul. One of the most common conversations I have is explaining why a horse isn’t fully healed yet or why additional diagnostics and treatment are still necessary. Setting expectations early helps improve compliance and trust.

And whenever possible, pursue an accurate diagnosis through gastroscopy. The more precisely you can characterize the ulcers you’re treating, the better you can tailor therapy, improve outcomes, and make informed recommendations for long-term management.

Thank you, Dr. Jamieson, for sharing your expertise and helping shed light on the complexities of equine gastric disease!

Product Brochure 

Discover how our injectable omeprazole suspension is helping veterinarians streamline equine gastric ulcer treatment.

Download a copy of our brochure for yourself or to share in your practice.

Upcoming Webinar

Injectable Omeprazole in Equine Gastric Disease: An Expert Panel Q&A

On-Demand Webinar

Long-Term Management of EGUS in Performance Horses

Injectable Omeprazole in Equine Gastric Disease: An Expert Panel Q&A

November 11 | 8 p.m. ET

RACE-Approved CE Credit Hours: 1
Free to attend

Equine gastric ulcer syndrome remains one of the most common and challenging conditions in equine practice. In this interactive panel webinar, Dr. David Rendle and Dr. Camilla Jamieson will draw on published research and their clinical experience to answer practitioners’ questions about extended-release injectable omeprazole. Questions submitted by attendees in advance will guide the discussion, which will cover case selection, pharmacology, dosing intervals, injection site selection and reaction management, combination therapy, and appropriate treatment duration. Participants will leave with practical, evidence-based guidance they can apply directly to managing equine glandular and squamous gastric disease.

Diagnosis and Management of Equine Metabolic Syndrome

October 22 | 8 p.m. ET

RACE-Approved CE Credit Hours: 1
Free to attend

This lecture will describe the means and methods necessary to properly identify and diagnose Equine Metabolic Syndrome (EMS). The lecture will also outline the differences between other metabolic disorders. A proper physical exam to identify phenotypical features of the affected horse along with detailed lab work will be key topics of the lecture. The lecture will also cover, in detail, important aspects of exercise, feed and medications necessary to manage these cases.

Long-Term Management of EGUS in Performance Horses

This informative webinar explored the management of Equine Gastric Ulcer Syndrome (EGUS) in performance horses, including evidence-based approaches to acid suppression and ulcer healing. The session covered practical treatment considerations, strategies to help reduce recurrence through dietary, environmental, and training management, and the importance of medication stewardship. Attendees also learned how integrating pharmacologic therapy with proactive management can support sustainable, long-term control of EGUS.

Compounding Confidence and Clarity: Practical Decision-Making for Equine Veterinary Compounds

By the end of this session, equine veterinarians were equipped with actionable strategies to reduce therapeutic failures, better manage drug testing risk, improve client communication, and make safer, evidence-based decisions when prescribing compounded medications.

Diagnosis and Management of Equine Metabolic Syndrome

This lecture covered the identification and diagnosis of Equine Metabolic Syndrome (EMS), including how it differs from other metabolic disorders. Key topics included physical exam findings, diagnostic lab work, and management strategies involving exercise, nutrition, and medication.

Epicur Pharma and Bova Partnership

In 2022, Stokes Healthcare formed a partnership with Bova Global which would bring their unique formulations of medications to the US.

The Bova Group comprises Bova Aus and Bova UK. Bova Aus has been operational since 1968 and is the largest veterinary compounder in Australia, catering to numerous veterinarians nationwide. Bova Aus has implemented a robust quality assurance system for popular, high-risk, and complex compounded products in collaboration with the Australian Pesticides and Veterinary Medicines Authority (APVMA) to ensure compliance with prevailing regulations, adhering to USP or BP pharmacopoeia standards for quality control.

In 2017, Bova expanded operations to the UK with Bova UK, a Specials Manufacturer focused on delivering high-quality Specials Medications to the UK veterinary sector. Authorized by the Veterinary Medicines Directorate, the facilities obtained a Manufacturer ‘Specials’ Authorisation (ManSA) in 2017 for both sterile and non-sterile medicines. The company upholds stringent quality standards compliant with current Good Manufacturing Practices (cGMP) and Good Laboratory Practices (GLP) as outlined by the European Medicine Standards. 

Made possible by our partnership, Epicur Pharma is manufacturing the only injectable omeprazole formulation identical to the Bova formulation used in clinical studies across the globe. 

When I was looking for a partner to bring our unique formulations to the US, it was critical to me to find a partner that took science and quality as serious as Bova does. When I met the team at Stokes, I couldn’t have been happier. I’ve been to the facilities several times to inspect them, and I can assure you they are taking this extremely seriously. After they made the product, they sent it to us to assure that they were meeting the Bova specifications. So you can be confident in the quality of the medicines that are produced at Stokes Healthcare.
Nick Bova
CEO of Bova Global

Why Partner With Us

Epicur is dedicated to helping veterinary professionals advance the industry and improve patient care. Our commitment to raising the standard of care in animal health is in the quality of every medication we manufacture. 

503A vs 503B Flowchart

Our flowchart can help you figure out which compounding facility is best for each patient’s prescription and office order!

Want the front & back version? Download it here!

Our Family of Brands

Stokes Healthcare has prepared medications for your individual patients since 1975 through Stokes Pharmacy. Recognizing the evolving needs of veterinary practices as regulations and
laws changed, including GFI 256 and USP guidelines, we expanded to include Epicur Pharma to serve the needs of many of your patients with standardized and tested bulk medications.

Each of our brands operates with key differences that impact your patient care and influence treatment plans, but they are all unified in their commitment to quality and improving patient outcomes with medication you trust. You can be confident in your patient care when you partner with us, knowing there is consistency and reliability in every medication.

Patient Orders:
800.754.5222

Office Orders:
888.508.5032 or dto@epicurpharma.com